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ABSTRACT
Objective: The aim of this study was to assess the potential drug interactions among hospitalized patients in cardiac and pulmonary wards in three 
tertiary care hospitals.
Methods: A prospective, observational study was carried out for 12 months. A sample of 1150 patients were assessed for potential drug-drug 
interactions (pDDIs) using Micromedex®- 2.7 and Drugs.com.
Results: A total of 1150 patients were analyzed, and it was found that 685 were cardiac and 465 were pulmonary patients. The study identified 
524 (76.49%) cardiac patients and 345 (74.19%) pulmonary patients, with pDDIs higher in male cardiac (298 [56.87%]) and male pulmonary (199 
[57.68%]) patients, compared to females. Incidences of pDDIs were found to be higher in the age group of 60–70 years in cardiac (193 [36.83%]) 
and pulmonary (146 [42.31%]) patients and incidences of interactions based on duration of 4–6 days’ hospital stays in cardiac were 380 (72.53%) 
and 215 (62.31%) in pulmonary patients, respectively. Moreover, 51.90% of cardiac patients and 56.52% of pulmonary patients were found to be 
prescribed with more number of drugs (cardiac 7 drugs and pulmonary 5–6 drugs) causing higher incidences of pDDIs. Some of the most common 
drug interacting pair was aspirin and clopidogrel combination observed in 245 cardiac patients, whereas in the pulmonary department, it was 
ranitidine-theophylline combination with a frequency of 195 pDDIs. Drug-food interactions were found with atorvastatin–citrus fruits in cardiac and 
theophylline–caffeine in pulmonary patients. The most common drug-disease interaction was found to be isosorbide dinitrate–myocardial infarction 
in cardiac and diazepam–COPD in pulmonary, respectively.
Conclusion: Pharmacists must take responsibility in the monitoring of drug interactions and notifying the physician and patient about potential 
problems. With their detailed knowledge of drugs, pharmacists have the ability to relate unexpected symptoms experienced by patients to possible 
adverse effects of their drug therapy.
Keywords: Cardiac, Drug-drug interactions, Pulmonary, Aspirin, Clopidogrel, ISDN–MI.
INTRODUCTION
A drug interaction occurs when a patient’s response to a drug is 
modified by food, nutritional supplements, formulation excipients, 
environmental factors, other drugs, or disease. Drug interactions are 
a major area of concern these days. The study of drug-drug, food-
drug, and disease-drug interactions and of genetic factors affecting 
pharmacokinetics and pharmacodynamics is expected to improve 
drug safety and will enable individualized drug therapy. Drug-drug 
interactions are said to account for a number of severe adverse drug 
reaction, resulting in hospitalizations and emergency department 
visits. It is estimated that, in 2011, DDI contributed to about 56.4% 
of all ADR [1]. Furthermore, ADR due to DDI accounts for about 
2.8% hospital admission every year [2]. Many adverse events can 
be prevented by identifying potential drug interactions (pDIs). 
However, certain conditions such as multiple disorders, chronic 
diseases, and polypharmacy may increase the risk of potential drug-
drug interaction. In the elderly, concomitant use of several drugs 
(polypharmacy) is very common and carries a high risk of both drug-
drug interaction and drug-disease. A study in 2010 reported that 
558 (26.5%) of elder people taking medicines were exposed to at 
least one DDI [3]. It was reported in 2011 that 164 (75.9%) patients 
taking 7 or more drugs were having at least one potential drug-drug 
interactions (pDDIs) while 76 (73.8%) patients with a hospital stay of 
seven or more were at risk of DDIs [4]. Patients with cardiovascular 
disorders are even at higher risk of DDI due to the number and 
types of drug they receive and the influence of heart disease on drug 
metabolism. A prospective study conducted in one of the teaching 
hospitals in India in 2011 indicated that the incidence of pDI among 
cardiac drugs in hospitalized patients is 30.67% [5]. A cross-sectional 
study conducted in the Pulmonology Department, Ayub Teaching 
Hospital, Pakistan, in 2011 showed that among 558 pDDIs, most were 
of moderate (53.6%) or major (34%), good (74.2%) or fair (16.3%), 
and delayed onset (70%) [4].
Diet and lifestyle can sometimes have a significant impact on drugs. 
These may occur of accidental misuse or due to lack of knowledge about 
the active ingredients involved in the relevant substances. Interactions 
between food and drugs may inadvertently reduce or increase the drug 
effect. Major side effects of some diet (food) on drugs include alteration 
in absorption of fatty, high protein, and fiber diets. Sixteen cohort 
and case–control studies reported an elevated risk of hospitalization 
in patients who were exposed to pDDIs [6]. Studying the drug-drug 
interactions, food-drug interactions, and disease-drug interactions is 
essential for the management of drug therapy. The exhaustive literature 
review revealed that studies have been conducted on the pDDIs in the 
departments. Hence, we carry out a study to assess the prevalence 
of drug-drug interactions, food-drug interactions, and disease-drug 
interactions .
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i5.25081
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METHODS
The research was conducted in three tertiary care hospitals, in Erode, 
for 12 months at the hospitalized cardiac and pulmonary patients. 
1150 patients were taken in for the study, of which 685 were cardiac, 
and 465 were pulmonary patients. Exclusion criteria included out 
patients, patients <18 years of age, medical disability, and patients 
who are on Ayurveda, Siddha, or other alternative system of medicine. 
Consent was obtained from hospital authority and hospitalized 
patients. The data were collected from case sheets of hospitalized 
patients and direct patient interview from cardiac and pulmonary 
departments. Demographic information (age and sex), length of hospital 
stay, main diagnosis, number of drugs, and details of comorbidities 
were obtained from the clinical records. All medications that were 
prescribed, including routine and pro re nata (means as required) 
medications, were screened for pDDIs. pDDIs were detected using the 
Drug Interactions Checker within Micromedex®-2.7 and www.drugs.
com. The detected DDIs were classified as major, moderate, and minor, 
relying on their severity of clinical significance and cross-over checked 
manually for the presence of enough published medical evidence for 
the recognized interacting marketers. Primarily, based on the profile of 
medicines prescribed, the DDIs had been recognized and classified in 
step with the Micromedex®- 2.7 and www.drugs.com. In line with the 
types, pDDIs have been categorized as: Pharmacokinetics - absorption, 
distribution, metabolism, and excretion and pharmacodynamics 
- antagonism, synergism, and additive. In line with severity, pDDIs were 
labeled as: Major - the consequences are probably life threatening or 
capable of inflicting permanent harm; moderate - the outcomes may 
also cause deterioration in patients’ scientific fame and additional 
treatment or extension of hospital stay; and minor- the consequences 
are typically moderate. The effects can be bothersome or unnoticeable, 
but need to now, not considerably affect the healing outcome. 
Frequencies expressed as possibilities were used to summarize sex, 
diagnosis, number of medication disbursed frequency of pDDIs, the 
drugs concerned with the pDDIs, period of hospital stay and types, and 
severity of pDDIs.
RESULTS
A total of 1150 patients were admitted at the department of cardiac 
and pulmonary during the study period. Among these, 685 were 
cardiac and 465 were pulmonary patients. Of 685 cardiac patients, 
524 (76.49%) had found to be pDDIs, 856 pDDIs were found at 524 
cardiac patients, and 675 pDDIs were found at 465 pulmonary patients. 
It was found that patients were confirmed with minimum one or two 
pDDIs in both cardiac and pulmonary patients. Of which, 298 (56.87%) 
cardiac males and 199 (57.68%) pulmonary males were found to be 
higher pDDIs, compared to females. Incidences of pDDIs were found to 
be higher in the age group of 60–70 years in cardiac (193 [36.83%]) 
and pulmonary (146 [42.31%]) patients and incidences of interactions 
based on duration of (4–6 days) hospital stay were 380 (72.53%) 
and 215 (62.31%) in cardiac and pulmonary patients, respectively. 
51.90% of patients prescribed with more than seven drugs in cardiac 
and 56.52% of patients prescribed with between five and six drugs in 
pulmonary patients were found to have developed a higher number of 
pDDIs (Table 1).
On average, each patient had one or two coded diagnosis in which 
hypertension was the most common condition 165 (31.48%), followed 
by angina with diabetes mellitus 111 (21.18%) in cardiac patients and 
asthma 92 (26.66%), followed by the asthma with LRTI 75 (21.73%) in 
pulmonary patients (Tables 2-11).
DISCUSSION
DIs are a major area of concern these days for the effective management 
of patient illness. It may create a considerable health hazard to the 
patients when the risk-benefit ratio of combining interacting drugs 
is not accurately estimated. It has already been approximated that 
the effect of drug interactions can range from any minor morbidity 
to fatal consequences. The study of drug-drug, drug-food, and drug-
disease interactions and genetic factors affecting pharmacokinetics and 
pharmacodynamics is expected to improve drug safety and will enable 
individualized drug therapy.
The present study identified a total of 1150 patients admitted at 
the department of cardiac and pulmonary, during the study period. 
Among these, 685 were cardiac and 465 were pulmonary patients. 
Of 685 cardiac patients, 524 (76.49%) had found to be pDDIs, 856 
pDDIs were found in 524 cardiac patients (Fig. 1). 675 pDDIs were 
found in 465 pulmonary patients. Out of which 298 (56.87%) cardiac 
male, and 199(57.68%) pulmonary male were found to be higher 
pDDIs, compared to females (Table 1), similar to the study conducted 
by Mukesh et al, where male patients (67%) had a high frequency of 
cardiovascular incidence as compared to female patients (33%) [7]. 
Another study conducted by Murtaza et al. also reported that male 
patients had a higher cardiology (50.94%), pulmonary (56.41%), and 
pDDIs possible when compared to females in the present study may 
be the primary reason [8]. Another reason possibly will be the greater 
risk of cardiovascular and pulmonary disorders among male gender 
in comparison to female, and hence, there is a need for multiple drugs 
which ultimately result in drug interactions.
The study showed that the majority of the incidences of pDDIs were 
found to be higher in the age group of 60–70 years in 193 (36.85%) 
cardiac and 146 (42.33%) pulmonary patients (Table 1). A study 
conducted by Chelkeba et al. reported an age group of 59–69 years [9], 
whereas a study conducted by Fita et al. reported that the majority of 
patients ages were between 70 and 74 years [10]. Older people were at 
high risk of developing an ADR due to pDDIs for several reasons. They 
are likely to have higher commodities and thus take several prescriptions 
and over the counter drugs. As people get older, the liver loses the ability 
to metabolize drugs. Furthermore, older people are more than twice as 
susceptible to ADRs as younger people. As people age, the amount of 
water in the body decreases and the amount of fat tissue relative to water 
increases. Furthermore, as people age, the kidneys are less able to excrete 
drugs into the urine, and the liver is less able to metabolize many drugs.
The study revealed 72.53% of cardiac and 62.31% of pulmonary cases, 
that the number of hospital stay was between 4-6 days (Table 1). 
Lubinga et al, conducted a study which showed that the majority of 
the cases the number of hospital stay were less than 6 days [11]. The 
likelihood of getting the multiple drugs increases with the increased 
length of hospital stay which in turn will increase the likelihood of 
pDDIs.
In our study, 51.90% of patients were prescribed with more than seven 
drugs in the cardiology department (Table 1). The study conducted by 
de Andrade et al. revealed that 40.6% of cases were prescribed between 
13 and 16 drugs [12]. 56.52% of patients prescribed with between 5 
and 6 drugs in the pulmonology department. A study conducted by 
Ismail et al. showed that 54% of cases had more than seven drugs 
prescribed [4]. Mannesse et al. reported the concurrent use of three 
or more drugs increased the risk of ADE’s by 9.8 times [13]. More the 
medications that are prescribed, the more the possibility of irrational 
polypharmacy. A study conducted by Doan et al. determined the 
probability of potent cytochrome P450 (CYP 450) interactions in older 
hospitalized people taking more than five concurrent medicines [14]. 
Potential drug-drug interactions were present in 80% of people taking 
more than five concurrent medicines. People taking five concurrent 
medicines had a 50% probability of at least one drug interaction, each 
additional medicine adds a 12% increase in the risk of drug interactions.
The most common interacting pair at the cardiac department was 
found to be aspirin and clopidogrel, causing major pharmacodynamic 
interaction, with a frequency of 245 (Table 3). The finding of the study 
is similar to the study conducted by Murtaza et al., in which the most 
common interacting pair was identified as aspirin–clopidogrel followed 
by clopidogrel–fondaparinux [8]. Another study conducted by Yanti et al. 
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observed a combination of diltiazem–amlodipine and spironolactone–
potassium chloride [5]. Diltiazem may increase the serum amlodipine 
level by affecting CYP3A4, while the combination of spironolactone and 
potassium chloride will potentially increase potassium levels. The most 
common interacting pair at a pulmonology department in the present 
study was ranitidine–theophylline, which is a minor pharmacokinetic 
interaction, with a frequency of 195 (Table 4). Another study conducted 
by Ismail et al. showed dexamethasone–rifampicin as the most common 
interacting pair [4]. Rifampin can reduce the pharmacological effects 
of corticosteroids (dexamethasone and prednisolone). It is suggested 
to monitor corticosteroid effects and increase the dose if necessary. 
A dose reduction may be necessary if rifampin is discontinued.
Table 1: Demographic profile of cardiac and pulmonary patients
Parameter Cardiac total number of patients n=524 (%) Pulmonary total number of patients n=345 (%)
Gender-wise distribution
Male 298 (56.87) 199 (57.68)
Female 226 (43.13) 146 (42.32)
Age-wise distribution
18–30 21 (4.00) 33 (9.56)
31–45 69 (13.17) 35 (10.14)
46–59 164 (31.29) 86 (24.93)
60–70 193 (36.85) 146 (42.33)
Above 70 77 (14.69) 45 (13.04)
Number of hospital stay (in days)
<3 83 (15.83) 85 (24.63)
4–6 380 (72.53) 215 (62.31)
>7 61 (11.64) 45 (13.06)
Number of prescribed drugs per day
<4 94 (17.93%) 54 (15.65)
5–6 158 (30.15) 195 (56.52)
>7 272 (51.90) 96 (27.82)








PD Major 245 (28.62)
T. aspirin+ 
T. enalapril
PD Moderate 69 (8.06)
T. atorvastatin+ 
T. clopidogrel
PK Moderate 78 (9.11)
T. aspirin+ 
T. atenolol
PD Moderate 25 (2.92)
T. clopidogrel+ 
T. amlodipine
PK Moderate 80 (9.34)
T. atenolol+ 
T. metformin
PK Major 25 (2.92)
T. spironolactone+ 
T. enalapril
PD Moderate 18 (2.10)
T. enalapril+ 
T. metformin
Unknown Major 15 (1.75)
T. enalapril+ 
T. furosemide
PD Moderate 12 (1.40)
T. aspirin+ 
T. spironolactone
PD Major 41 (4.78)
PD: Pharmacodynamics, PK: Pharmacokinetics, pDDIs: Potential drug-drug 
interactions
Table 2: Types of diseases in each department
Cardiology (n=524) Pulmonary (n=345)
Type of diseases Number of patients Type of diseases Number of patients
Myocardial infarction 87 (16.60) Asthma 92 (26.66)
Angina+diabetes mellitus 111 (21.18) Asthma+LRTI 75 (21.73)
Hypertension 165 (31.48) Pneumonia 48 (13.91)
Ischemic heart disease 46 (08.77) Pneumonia+bronchitis 34 (09.85)
Coronary artery disease 34 (06.48) Bronchitis 47 (13.62)
Chronic heart failure 81 (15.45) COPD 49 (14.20)
LRTI: Lower respiratory tract infection, COPD: Chronic obstructive pulmonary disease
Fig 1: Distribution of drug interactions in various departments
Fig 2: Prevalence of potential drug‑drug interactions
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The prevalence of pDDIs in the cardiac department in our study was 
53.27% (Table 7 and Fig. 2). A similar study performed by Ismail et 
al. showed an overall 77.5% PDDI prevalence rate among randomly 
selected cardiac patients [4]. A study conducted by Murtaza et al. in 
the department of cardiology showed that the prevalence rate of PDDIs 
was 91.6% among the studied cardiac patients [8]. The prevalence of 
pDDIs in the pulmonary department in our study was 48.29% (Table 7). 
A similar study that was conducted by Ismail et al. reported an overall 
prevalence of 45% [4].
In our study, the prevalence of pDDIs was higher in major severity 
accounted at 456 (53.27%) cardiology and 326 (48.29%) pulmonary 
patients. Fokter et al. reported pDDIs of major severity in 13% of 
patients [15] and Ismail et al. in 24.25% of patients [3]. Prevalence 
of pDDIs of moderate severity was 30.94%. Patel et al. reported 
moderate severity in 60.3% of patients [5]. This study contrasts 
the other studies which report moderate severity. These potential 
DDIs suggest that there is a need for modification or alteration of 
therapy such as dosage adjustment. To prevent these DDIs, health-
care providers should have adequate information about DDIs not 
only through drug information center, which can provide evidence-
based information to health-care professionals, but also through 
encouraging the empowerment of clinical pharmacists that can 
provide an evidence-based approach to drugs and thereby prevent 
drug therapy problems of which DDIs is one.
Of 524 cardiac cases, there were 82 interacting pairs identified during 
the study. Among 856 pDDIs, 256 (29.90%) were due to pharmacokinetic 
interactions, and 456 (53.27%) were pharmacodynamic interactions. 
71 (8.29%) show both mechanisms and 73 (8.54%) were due to 
unknown mechanisms. Among 256 pharmacokinetic drug interactions, 
39 (15.23%) were due to absorption, 41 (16.01%) were due to 
distribution, 141 (55.07%) were due to metabolism, and 35 (13.67%) 
were due to excretion. Among 456 pharmacodynamic interactions, 
28 (6.14%) were synergistic, 115 (25.21%) were antagonistic, 
294 (64.47%) were added, and 19 (4.18%) with both additive and 
antagonistic effects. According to Chavda et al., among 423 pDDIs, 
50.83% were pharmacodynamic drug interactions, 38.53% were 
pharmacokinetics, and 10.64% were both kinds of mechanisms 
(Fig. 3) [16]. From 163 pharmacokinetics pDDIs, 45.41% were altered 
the absorption, 28.99% were altered the metabolism, and 25.60% were 
altered the excretion. Of the 215 pharmacodynamic pDDIs, 67.44% 
were synergistic, 30.70% antagonistic, and 1.86% unknown in nature. 
The reason for the majority being pharmacodynamic interaction is that 
these types of interactions derive from modification of the action of one 
drug at the target site by another drug, independent of a change in its 
Table 4: Interactive effect, M.O.A, clinical management of common potential drug‑drug interactions in cardiology
pDDI combination Mechanism of action Interactive effect Clinical management
T. aspirin+T. clopidogrel Increased risk of bleeding Additive effect Monitor for blood counts if coadministration is 
needed
T. aspirin+T. enalapril Decreased effectiveness of 
enalapril
Antagonistic effect Weigh benefit and risk
T. atorvastatin+T. clopidogrel Decreased formation of 
the clopidogrel active 
metabolite resulting in 
higher on-treatment platelet 
reactivity
Metabolism Discontinue the statin and substitute a statin 
that is not metabolized by CYP3A4 (i.e, 
pravastatin or rosuvastatin)
T. aspirin+T. atenolol Decreased antihypertensive 
effect
Antagonistic effect Monitor for the patient’s blood counts and dose 
adjustment for beta blockers if necessary
T. clopidogrel+T. amlodipine Decreased antiplatelet 




The addition of cilostazol may reduce the 
potential harmful interactions




Monitor for patient’s glucose level
T. spironolactone+T. enalapril Result in hyperkalemia Additive effect Monitor for serum potassium level
T. enalapril+T. metformin Increased risk of 
hypoglycemia
Unknown mechanism Avoid concurrent use
T. enalapril+T. furosemide Result in postural 
hypotension
Synergistic effect Discontinue the diuretic 2 or 3 days before ACEI
T. aspirin+T. spironolactone Result in hyperkalemia, or 
possible nephrotoxicity
Additive effect Avoid aspirin doses of>650 mg daily in adults 
receiving spironolactone
pDDIs: Potential drug-drug interactions
Fig 3: Classification of types of potential drug‑drug interactions
Table 5: Highest potential drug‑drug interaction combinations 
in pulmonary













PK Major 82 (12.14)
C. omeprazole+ 
T. clopidogrel




Unknown Minor 86 (12.74)
pDDIs: Potential drug-drug interactions
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concentration. This may result in enhanced response (synergism), an 
attenuated response (antagonism), or an abnormal response.
Of 345 pulmonary cases, 68 interacting pairs were identified during 
the study. Among 675 pDDIs, 202 (29.92%) were pharmacokinetic 
interactions, 416 (61.62%) were pharmacodynamic interactions. 
38 (5.62%) show both mechanisms, and 19 (2.84%) were unknown 
mechanism. Among 202 pharmacokinetic drug interactions in pulmonary 
department, 114 (56.43%) were due to metabolism. Among 416 
pharmacodynamic interactions, 276 (66.34%) were synergistic, identified 
to a study reported by Chavda et al, where 67.44% were synergistic 
followed by 30.7% antagonistic [16]. From pDDIs detected in the study by 
Chavda et al., the majority were of pharmacodynamic (58.83%) in nature, 
followed by pharmacokinetics (38.53%) interactions [16]. These findings 
are in contrast to the study reported by Vonbach et al. [17] and Aparasu 
et al., wherein, it was reported that 76% of pharmacokinetics and 22% of 
pharmacodynamic interactions (Fig. 3) [18].
Diet and lifestyle can sometimes have a significant impact on drugs. 
These may occur out of accidental misuse or due to lack of knowledge 
about the active ingredients involved in the relevant substances. 
Interactions between food and drugs may inadvertently reduce or 
increase the drug effect. Major side effects of some diet (food) on drugs 
include alteration in the absorption of fatty, high protein, and fiber diets.
According to this study, a total of 1150 patients were studied at 
cardiology and pulmonary departments. Among this, 685 were 
cardiac and 465 were pulmonary patients. Of 685 cardiac patients, 
290 (42.33%) were found to be drug-food interactions (DFIs). 457 
pDFIs were found in 290 cardiac patients. 278 pDFIs were found in 
165 pulmonary patients. The most common pDFIs were between 
atorvastatin and citrus fruits, in cardiac patients, with a frequency 
of 144 (Table 8), which may cause decreased first-pass metabolism 
and increased bioavailability of atorvastatin that further results in 
muscle breakdown, liver damage, digestive problems, increased blood 
sugar, and neurological side effects. The reason for these interactions 
is due to furanocoumarins. The interaction between citrus fruits and 
medications poses dangers only if a drug is taken orally because the 
interaction occurs in the digestive tract. The second most common 
interaction was banana interacting with the ACE inhibitors, with a 
frequency of 83, to cause hyperkalemia [19]. Bananas are high in 
potassium. Too much potassium can cause an irregular heartbeat and 
heart palpitations.
Of 278 pDFIs, 165 were found in pulmonary patients. The most common 
pDFIs were found between theophylline and caffeine (coffee/tea) with 
a frequency of 120 (43.16%) (Table 9), followed by theophylline–
protein-rich foods (fish, milk, and egg) with a frequency of 55 (19.78%). 
Tse et al. conducted a study that suggested that interactions between 
theophylline and caffeine may be attributed to changes in drug 
distribution and drug elimination characteristics [20].
A total of 1150 patients were studied at cardiology and pulmonary 
departments. Among these, 685 were cardiac and 465 were pulmonary 
patients. Of 685 cardiac patients, 175 (42.06%) had found to be pDDIs. 
289 pDDIs were found in 175 cardiac patients. 138 pDDIs were in 
93 (22.35%) pulmonary patients. The most common drug-disease 
interaction was found between ISDN and MI (Table 10). The interaction 
may result in systemic hypotension and tachycardia. It may also 
exacerbate myocardial ischemia. The second common drug-disease 
interaction was found to be furosemide with DM. This interaction may 
result in latent diabetes which may become overt: Insulin requirements 
in established diabetes may increase. Therefore, it is advisable to stop 
furosemide before a glucose tolerance test. The most common pDDIs 
found between diazepam and COPD in pulmonary patients (Table 11). 
This interaction may result in risk of respiratory depression. Dimitriadis 
et al. conducted a study which reported that the effects of furosemide 
may contribute to the decrease in glucose utilization [21].
Table 6: Interactive effect, M.O.A, clinical management of common potential drug‑drug interactions in pulmonology
pDDI combination Mechanism of action Interactive effect Clinical management
Injection ranitidine+Injection 
theophylline
Theophylline toxicity (nausea, vomiting, 
palpitations, seizures)
Decrease metabolism Dosing adjustments of 




Result in hypokalemia Antagonistic effect; additive 
effect
Potassium balance should 





Theophylline toxicity (nausea, vomiting, 
palpitations, seizures)
Decreased metabolism Serum levels of 
theophylline should be 
monitored and dosage 
adjustments made as 
appropriate
C. omeprazole+T. clopidogrel Reduction in clinical efficacy of 
clopidogrel and increased risk for 
thrombosis
Inhibit metabolism Avoid concomitant 
use of clopidogrel 
and omeprazole. 
Rabeprazole (given 4 
hours after clopidogrel), 
pantoprazole, and 
dexlansoprazole have less 




Altered theophylline concentrations Unknown Dosing adjustments of 
theophylline may be 
necessary
pDDIs: Potential drug-drug interactions
Table 7: Prevalence of pDDIs
Type of prevalence Cardiology Pulmonary
Severity of pDDIs Frequency 
n=856 (%)
Frequency n=675 (%)
Major 456 (53.27) 326 (48.29)
Moderate 251 (29.33) 217 (32.16)
Minor 149 (17.40) 132 (19.55)
pDDIs: Potential drug-drug interactions
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CONCLUSION
This study concluded that the overall incidence of the pDDIs was very 
high in cardiology when compared to pulmonology department. It was 
found that the incidence of pDDIs was associated with older age, male 
gender, number of medication given, and increased length of hospital 
stays. To reduce pDDIs, the number of medications for the patients 
need to properly controlled and it is recommended to eliminate all 
medications without therapeutic benefit, the goal, and indication. 
All potential DDIs are not equally harmful; therefore, identification 
of the level of each potential DDIs is integral to assess the clinical 
importance and appropriate management. Food-drug interactions can 
produce negative effects on the safety and efficacy of drug therapy as 
well as nutritional status of patients. Often, such interactions can be 
avoided by taking 1 h before or 2 h after eating. Therefore, providing 
information regarding the different food and drug interactions will help 
the physicians to prescribe drugs cautiously with only suitable food 
supplement to get maximum benefit for the patient. Our study reports 
several examples of interactions between drugs and diseases. Guideline 
developers could consider a more systematic approach regarding the 
potential for drug-disease interactions, based on epidemiological 
knowledge of the commodities of people with the disease, the guideline 
is focused on and should particularly consider whether cardiovascular 
diseases are common in the target population. Knowledge of such 
predictable or possible interactions is necessary for their timely 
detection and prevention of associated morbidity.
Pharmacists must take responsibility for observing for drug interactions 
and informing the doctor and the patient about potential issues. With 
their point-by-point information about drugs, pharmacists have the 
capacity to relate unforeseen side effects experienced by patients 
inconceivable adverse effects of their drug therapy.
Table 8: Distribution of potential DFIs in cardiology
Drug‑food Interactive effect Type of DFI Severity Frequency n=457 (%)
T. atorvastatin with citrus fruits Decreased first-pass metabolism and increased 
bioavailability
PK Moderate 144 (31.50)
T. enalapril with banana Hyperkalemia Unknown Moderate 47 (10.28)
T. atenolol with orange juice Decrease the mean peak plasma concentration of 
atenolol; excretion of drugs in urine decreased
PK Moderate 79 (17.28)
T. diazepam with tea/coffee Antagonistic effect. Caffeine generally antagonized 
the diazepam-induced ratings of sedation and 
impairment of psychomotor performance
PD Minor 83 (18.16)
T. Bisacodyl with milk Increase the risk of stomach upset and nausea Unknown Minor 91 (19.91)
T. paracetamol with cabbage Decrease effectiveness of the drug PK Moderate 38 (8.31)
Table 9: Distribution of potential DFIs in pulmonology
Drug‑food Interactive effect Type of DDI Severity Frequency n=278 (%)
T. theophylline with coffee/tea (caffeine) Increased plasma concentration by 
inhibiting metabolism
PK Moderate 120 (43.16)
T. theophylline with protein-rich 
foods (fish, milk, egg, meat)
Increased clearance of the drug Unknown Moderate 55 (19.78)
T. paracetamol with cabbage Decrease effectiveness of the drug. PK Moderate 22 (7.91)
T. ciprofloxacin with tea/coffee (caffeine) Increased caffeine concentrations and 
enhanced CNS stimulation
PK Moderate 68 (24.46)
T. ciprofloxacin with milk/curd Decreased drug concentration PK Moderate 65 (23.38)
DFIs: Drug-food interaction
Table 10: Distribution of potential drug‑disease interactions in cardiology
Drug‑disease Interactive effect Severity Frequency n=289 (%)
T. ISDN with MI Systemic hypotension and tachycardia Major 42 (14.53%)
Injection furosemide with diabetes 
mellitus
Latent diabetes may become overt: Insulin requirements in 
established diabetes may increase: Stop furosemide before a 
glucose tolerance test
Moderate 56 (19.37)
T. atenolol with DM Inhibit catecholamine-mediated glycogenolysis, thereby 
potentiating insulin-induced hypoglycemia and delaying the 
recovery of normal blood glucose levels
Major 24 (8.30)
T. enalapril with CHF Oliguria and/or progressive azotemia, and rarely, renal failure, 
myocardial ischemia, and death
Major 28 (9.68)
T. amlodipine with CAD Unknown mechanism Major 18 (6.22)
ISDN: Isosorbide dinitrate, MI: Myocardial infarction, DM: Diabetes mellitus, CHF: Congested heart failure, CAD: Coronary artery diseases
Table 11: Distribution of potential drug‑disease interactions in pulmonology
Drug‑disease Interactive effect Severity Frequency n=138 (%)
T. diazepam with COPD Risk of respiratory depression Moderate 76 (55.07)
T. chlorpheniramine with COPD Reduce the volume and cause thickening of bronchial 
secretions, resulting in obstruction of the respiratory tract
Moderate 62 (44.93)
COPD: Chronic obstructive pulmonary diseases
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